IL1RAP-Targeted ADC Shows Preclinical Promise in Ewing Sarcoma and Fusion-Driven Cancers
A new antibody-drug conjugate targeting IL1RAP has shown potent preclinical activity against Ewing sarcoma and other fusion-driven cancers, with minimal off-target toxicity. Researchers at UBC report tumor eradication and reduced metastasis, with clinical trials being planned.
Researchers at the University of British Columbia have engineered an antibody-drug conjugate (ADC) targeting IL1RAP that demonstrates potent antitumor activity in preclinical models of Ewing sarcoma and other malignancies driven by oncogenic fusions. The findings, published in Cancer Discovery, show the ADC eradicates established tumors, reduces metastatic dissemination, and exhibits a favorable safety profile, paving the way for early-phase human trials.
The ADC exploits IL1RAP, a cell surface antigen selectively overexpressed on malignant cells but strikingly absent from healthy tissues. By conjugating cytotoxic agents to monoclonal antibodies that specifically recognize IL1RAP, the therapy creates a molecular delivery system that ferries lethal payloads exclusively to cancer cells, sharply contrasting with conventional chemotherapies that indiscriminately affect normal tissue.
In preclinical models, the IL1RAP-directed ADC not only eliminated primary Ewing sarcoma tumors—a rare, aggressively metastatic bone cancer predominantly affecting children and young adults—but also significantly impaired metastatic competency. Therapeutic benefits extended beyond Ewing sarcoma, with potent antitumor activity observed in lymphoma and other cancers harboring oncogenic fusions such as NTRK gene rearrangements, underscoring the broad applicability of the approach.
The ADC’s safety profile is a key advance. Because IL1RAP expression is largely restricted to tumor cells, off-target toxicity is minimized. The design employs an optimized linker-payload system that keeps the cytotoxic agent inactive during systemic circulation, unleashing full potency only upon internalization into IL1RAP-expressing cancer cells.
IL1RAP acts as a protective shield that facilitates cancer cell survival in the bloodstream during metastasis, helping malignant cells endure oxidative stress, shear forces, and immune surveillance. By turning this adaptive mechanism into a therapeutic vulnerability, the research builds on earlier foundational studies elucidating IL1RAP’s role in metastasis.
With comprehensive preclinical toxicology and efficacy data now validating the approach, investigators are preparing early-phase human trials to confirm safety, dosing, and therapeutic window in patients. The ADC molecules, including ADV581-DXd and ADV101, were developed through industry collaborations with Advesya and DualityBio, highlighting the fusion of academic and biotech innovation.